Homepage > Company > Media > Pharma News > 2020 > Novo Holdings establishes rare bleeding disorder firm Hemab

Novo Holdings establishes rare bleeding disorder firm Hemab

Novo Holdings’ early-stage investment and company creation team Novo Seeds has established a new portfolio company – Hemab – which will focus on the development of bispecific antibodies for rare bleeding disorders.

The company, co-founded by former Novo Nordisk executives Johan Faber and Søren Bjørn, has secured an exclusive license to certain intellectual property to develop a product within haemophilia and other rare bleeding disorders from Novo Nordisk.

Hemab has also scored an exclusive license to Genmab’s bispecific DuoBody platform technology, which will help the company to develop further novel therapies for ultra-rare bleeding disorders.

"We are very pleased to have Novo Seeds on board as investor and partner to accelerate the development of our exciting new technology platform,” said Johan Faber, co-founder and chief executive officer of Hemab.

“We are passionate about developing novel therapies for people with severe bleeding disorders that are in high need for a prophylactic treatment option that is effective, safe and convenient. With the hands-on support of Novo Seeds we have a strong foundation to realize our ambitions for patients with rare bleeding disorders,” he added.

Jørgen Søberg Petersen, Novo Seeds Partner, will join Henmab as chairman and Camilla Petrycer Hansen, Novo Seeds Senior Associate, will also join the board.

In addition, Benny Sørensen, will join the board as an independent non-executive director.

Sørensen currently serves as senior vice president, head of clinical development at Codiak BioSciences.

16th December 2020

http://www.pharmatimes.com/

Read also

FDA approves AstraZeneca’s FASENRA for asthma in children

The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.

Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.